Author Archive: Roxan Olivas
Critical Path Institute and Citizen Health Partner to Accelerate Drug Development for Neuromuscular Disorders
SAN FRANCISCO and TUCSON, Ariz., May 29, 2025 — Critical Path Institute® (C-Path), a global nonprofit accelerating drug development through data science and regulatory innovation, and Citizen Health, a leading consumer health platform, today announced their new strategic collaboration. Together, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.Continue reading
Critical Path Institute Celebrates 20 Years of Advancing Drug Development through Innovation and Collaboration
TUCSON, Ariz., May 8, 2025 — The year 2025 marks a historic milestone for Critical Path Institute® (C-Path), as the organization celebrates 20 years of transforming the landscape of drug development through collaboration, regulatory science, and next-generation strategies. Continue reading
C-Path’s Predictive Safety Testing Consortium Advances a Transformative Test to Detect Drug Induced Liver Injury
Serum Glutamate Dehydrogenase Activity Enables Sensitive and Specific Diagnosis of Hepatocellular Injury in HumansContinue reading
C-Path Announces Paul E. Edmeier as New Chief Financial Officer
New CFO to Lead Financial Strategy and Global Compliance at C-PathContinue reading
C-Path Announces Successful Conclusion of the eCOA: Getting Better Together Initiative
Collaboration has culminated in meaningful, lasting changes for the benefit of stakeholders in the electronic collection of clinical outcome assessment data in clinical trialsContinue reading
C-Path’s CPA-1 Consortium Welcomes Newest Members Kamada, Sanofi
TUCSON, Ariz., February 18, 2024 — Critical Path Institute’s® (C-Path)Critical Path for Alpha-1 (CPA-1) consortium today announced the addition of biopharmaceutical companies, Kamada and Sanofi, as its newest members. Continue reading
C-Path Announces Jennifer Kendra as New Vice President of Strategic Relationships
New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-PathContinue reading
C-Path’s TRxA Announces 2025 Request for Proposals from Academic Investigators
New Funding Opportunity for Drug Development ProjectsContinue reading
C-Path’s TRxA Announces $1 Million Award for Drug Development Project in Type 1 Diabetes
TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B. Helmsley Charitable Trust, a new research grant aimed at developing a novel treatment for type 1 diabetes (T1D). This award is made through TRxA’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, which is designed to support academic researchers in traversing the drug development valley of death and advancing new cutting-edge therapeutics from the lab to patients. Continue reading